Motegrity works by activating serotonin receptors in your gut’s nervous system, triggering the muscular contractions that push stool through your colon. It’s the only prescription prokinetic approved in the U.S. for chronic idiopathic constipation in adults, and it takes a fundamentally different approach than most other constipation medications. Rather than drawing water into your intestines, Motegrity gets the muscles of your colon moving again.
The Serotonin Signal Behind Motegrity
Your gut has its own nervous system, sometimes called the “second brain,” and serotonin is one of its key chemical messengers. Motegrity (prucalopride) locks onto a specific type of serotonin receptor called 5-HT4, found on nerve cells embedded in the wall of your colon. When the drug activates these receptors, those nerve cells release acetylcholine, a chemical that tells the surrounding smooth muscle to contract.
These aren’t random squeezes. Motegrity promotes a specific type of contraction called high-amplitude propagating contractions: powerful, coordinated waves that travel the entire length of the colon, pushing its contents forward toward the rectum. Think of it like a conveyor belt restarting after being stalled. At the same time, the drug activates receptors on circular muscle in the colon and rectum that cause those muscles to relax, which helps contents pass through more easily. The combination of contraction in one direction and relaxation ahead of it is what creates effective propulsion.
How It Differs From Other Constipation Medications
Most prescription constipation drugs are secretagogues, meaning they work by pulling extra fluid into your intestines to soften stool and stimulate movement. Medications like linaclotide (Linzess) and plecanatide (Trulance) fall into this category. Over-the-counter osmotic laxatives like MiraLAX work on a similar water-drawing principle.
Motegrity is the only FDA-approved prokinetic for chronic constipation, which means it directly stimulates the muscular machinery of the colon rather than changing the fluid balance inside it. This distinction matters practically: if you’ve tried secretagogues without enough relief, Motegrity targets a completely different part of the problem. Some clinicians combine the two approaches, using a secretagogue alongside Motegrity to address both sluggish motility and stool consistency at once, though this is based on clinical experience rather than formal trial data.
How Quickly It Works
Motegrity can work surprisingly fast. In clinical studies, the median time to a first bowel movement after taking a dose was about 3 hours, compared to over 22 hours for patients taking a placebo. That said, the full therapeutic benefit builds over days and weeks as regular motility patterns are reestablished. The drug is taken once daily, and its half-life is roughly 24 hours, meaning it maintains a steady presence in your system with consistent dosing. Your kidneys handle most of the elimination, with 60 to 65% of the drug excreted unchanged in urine.
What the Clinical Trials Show
The goal in constipation trials is typically reaching three or more spontaneous complete bowel movements per week. Across multiple phase 3 studies, Motegrity consistently doubled the response rate compared to placebo. In an integrated analysis of six randomized trials covering nearly 2,500 patients, 27.8% of people on Motegrity hit that three-per-week threshold over 12 weeks, compared to 13.2% on placebo. One study of 374 patients saw even stronger results, with 37.9% responding to Motegrity versus 17.7% on placebo.
Those numbers may look modest at first glance, but chronic idiopathic constipation is notoriously difficult to treat, and many participants had already failed other therapies. The benefit also appears to hold up over time. A large real-world study found that six months after starting Motegrity, patients had significant reductions in abdominal pain (from 50.4% to 33.3%), bloating (23.9% to 13.3%), and nausea (22.6% to 17.7%). Constipation-related complications like hemorrhoids and rectal bleeding also dropped.
Common Side Effects
The most frequent side effects are headache, abdominal pain, and nausea, and they tend to be most noticeable in the first few days. In clinical trials of at least 12 weeks, headache occurred in 19% of patients on Motegrity versus 9% on placebo. Abdominal pain (including discomfort and tenderness) affected 16% compared to 11% on placebo, and nausea hit 14% versus 7%. For many people, these symptoms ease as the body adjusts to the medication.
The Mood-Related Warning
Motegrity carries an FDA warning about psychiatric effects that’s worth knowing about. Cases of suicidal thoughts, self-injurious ideation, and new or worsening depression have been reported in patients taking the drug. The FDA labeling instructs patients and their families to watch for unusual mood changes or behavioral shifts. If any of these symptoms appear, the guidance is to stop the medication immediately and contact a healthcare provider. This doesn’t mean the drug commonly causes depression, but the signal was significant enough to warrant formal monitoring recommendations.
How Motegrity Fits Into Treatment
Motegrity is approved specifically for chronic idiopathic constipation in adults, meaning constipation that isn’t caused by another medical condition or medication. It has not been studied or approved for use in children. The standard dose is 2 mg once daily, though a lower dose may be used for people with significant kidney impairment since the kidneys are the primary route of elimination.
In practice, Motegrity is typically considered after lifestyle changes and over-the-counter options like fiber supplements, osmotic laxatives, or stimulant laxatives haven’t provided adequate relief. Its unique mechanism makes it a particularly useful option for people whose constipation is primarily a motility problem, where the colon simply isn’t contracting forcefully or frequently enough to move things along.